Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a $6.3 billion deal, aiming to strengthen its neuroscience research and development capabilities. The transaction is expected to expand the drugmaker's pipeline in the treatment of

• Eli Lilly to acquire Centessa in $6.3B deal
• Expansion of neuroscience portfolio